{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:11:20Z","timestamp":1761487880987},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3499,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Cardiol"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1002\/clc.4960290203","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T05:01:12Z","timestamp":1183006872000},"page":"52-55","source":"Crossref","is-referenced-by-count":6,"title":["Ezetimibe: Rationale and role in the management of hypercholesterolemia"],"prefix":"10.1002","volume":"29","author":[{"given":"Leonid","family":"Yatskar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Schwartzbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1002\/clc.4960290203-BIB1","first-page":"A2","article-title":"The Munster Heart Study (PROCAM). Results of follow-up at 8 years","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960290203-BIB2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/clc.4960290203-BIB3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1002\/clc.4960290203-BIB4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2362.1987.tb01132.x","article-title":"Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population","volume":"17","author":"Kes\u00e4niemi","year":"1987","journal-title":"Eur J Clin Invest"},{"key":"10.1002\/clc.4960290203-BIB5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1002\/clc.4960290203-BIB6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1520-037X.2003.01691.x","article-title":"The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level","volume":"6","author":"Turley","year":"2003","journal-title":"Prevent Cardiol"},{"key":"10.1002\/clc.4960290203-BIB7","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/BF03216291","article-title":"Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism","volume":"40","author":"Einarsson","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/clc.4960290203-BIB8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","author":"The Lipid Research Clinics Program","year":"1984","journal-title":"J Am Med Assoc"},{"issue":"12","key":"10.1002\/clc.4960290203-BIB9","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/jn\/129.12.2109","article-title":"The cholesterol-lowering action of plant stanol esters","volume":"129","author":"Nguyen","year":"1999","journal-title":"J Nutr"},{"issue":"20","key":"10.1002\/clc.4960290203-BIB10","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1056\/NEJM199511163332002","article-title":"Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population","volume":"333","author":"Miettinen","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/clc.4960290203-BIB11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00041433-200012000-00002","article-title":"Therapeutic potential of plant sterols and stanols","volume":"11","author":"Plat","year":"2000","journal-title":"Curr Opin Lipidol"},{"issue":"8","key":"10.1002\/clc.4960290203-BIB12","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.103.8.1177","article-title":"AHA Science Advisory: Stanol\/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association","volume":"103","author":"Lichtenstein","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/clc.4960290203-BIB13","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/clc.4960290203-BIB14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.bjp.0704260","article-title":"Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function","volume":"134","author":"van Heek","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1002\/clc.4960290203-BIB15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1567-5688(01)80226-9","article-title":"Effect of ezetimibe on serum concentrations of lipid-soluble vitamins (abstr)","volume":"2","author":"Knopp","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1002\/clc.4960290203-BIB16","unstructured":"Zetia (Ezetimibe): Prescribing information. Package insert. Merck\/Schering-Plough Pharmaceuticals, 2001"},{"issue":"6","key":"10.1002\/clc.4960290203-BIB17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0149-2918(01)80075-8","article-title":"A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe","volume":"23","author":"Ezzet","year":"2001","journal-title":"Clin Ther"},{"issue":"10","key":"10.1002\/clc.4960290203-BIB18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Esetimibe Study Group: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1002\/clc.4960290203-BIB19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Ezetimibe Study Group: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies","volume":"23","author":"Bays","year":"2001","journal-title":"Clin Ther"},{"issue":"10","key":"10.1002\/clc.4960290203-BIB20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Ezetimibe Study Group: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1002\/clc.4960290203-BIB21","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/clc.4960290203-BIB22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960290203-BIB23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1002\/clc.4960290203-BIB24","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"The American College of Cardiology\/American Heart Association\/National Heart, Lung and Blood Institute: ACC\/AHA\/NHLBI Clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/clc.4960290203-BIB25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/clc.4960290203-BIB26","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1161\/01.CIR.102.18.2165","article-title":"Direct proinflammatory effect of C-reactive protein on human endothelial cells","volume":"102","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"issue":"13","key":"10.1002\/clc.4960290203-BIB27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/01.CIR.0000061916.95736.E5","article-title":"C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"issue":"26","key":"10.1002\/clc.4960290203-BIB28","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study Investigators : Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1002\/clc.4960290203-BIB29","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"issue":"9326","key":"10.1002\/clc.4960290203-BIB30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/clc.4960290203-BIB31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid-lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960290203-BIB32","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atovastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"J Am Med Assoc"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960290203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/clc.4960290203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:54:25Z","timestamp":1625183665000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960290203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"URL":"https:\/\/doi.org\/10.1002\/clc.4960290203","relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}